Jason Lu

Executive Summary Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing. Compared to traditional biologics or small-molecule drugs, ADC production involves: biologics (antibodies) highly potent small molecules (payloads) complex conjugation chemistry As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottlenecks in drug...

Introduction: The Next Step of CAR-T Is Not “Better” — It’s “Simpler” Over the past decade, CAR-T therapy has proven that we can treat cancer with engineered immune cells. But the real bottleneck is never efficiency, but rather: Too high cost The manufacturing process is too slow Patients can't wait The essence of traditional CAR-T is actually "personalized cell manufacturing". Now, a more fundamental question has arisen: What if CAR-T didn't need to be manufactured at all? This is the...

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs typically...